NASDAQ:IDYA IDEAYA Biosciences Q3 2025 Earnings Report $28.56 -0.24 (-0.82%) As of 01:20 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast IDEAYA Biosciences EPS ResultsActual EPS$1.33Consensus EPS -$0.12Beat/MissBeat by +$1.45One Year Ago EPSN/AIDEAYA Biosciences Revenue ResultsActual Revenue$207.83 millionExpected Revenue$59.98 millionBeat/MissBeat by +$147.85 millionYoY Revenue GrowthN/AIDEAYA Biosciences Announcement DetailsQuarterQ3 2025Date11/4/2025TimeBefore Market OpensConference Call DateTuesday, November 4, 2025Conference Call Time6:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) IDEAYA Biosciences Earnings HeadlinesIDEAYA Biosciences, Inc.: IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 5 at 10:53 AM | finanznachrichten.deIDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 5 at 6:00 AM | prnewswire.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 6 at 1:00 AM | Brownstone Research (Ad)Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?May 4 at 7:26 AM | insidermonkey.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | prnewswire.comIDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR ...April 30, 2026 | finance.yahoo.comSee More IDEAYA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email. Email Address About IDEAYA BiosciencesIDEAYA Biosciences (NASDAQ:IDYA) is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications. Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies. This platform supports the rapid progression of drug candidates from target validation through early clinical development. IDEAYA has entered strategic collaborations with established pharmaceutical partners to expand the reach of its synthetic lethality portfolio, leveraging complementary expertise in drug discovery, development, and commercialization. Founded in 2016 and headquartered in South San Francisco, California, IDEAYA maintains research operations in the United States and collaborates with leading academic institutions and industry organizations worldwide. The company’s management team comprises experienced biopharmaceutical executives and oncology researchers who guide its mission to deliver precision medicines to patients with high-need cancers. IDEAYA continues to build on its scientific foundation to bring forward innovative treatments that address genetically defined subsets of tumors.View IDEAYA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageYears in the Making, AMD’s Upside Movement Has Just BegunWestern Digital: The Storage Behemoth Skyrocketing on AI DemandOld Money, New Tech: Western Union's Crypto RebootPinterest Pins a Profit Play To Its Mood BoardJust How Big a Problem Could Amazon’s Cash Burn Rate Be?BlackBerry Rewrites Its Own Operating System Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)argenex (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
